Key statistics
On Friday, Organon & Co (7XP:MUN) closed at 6.19, 12.05% above the 52 week low of 5.53 set on Oct 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.19 |
|---|---|
| High | 6.19 |
| Low | 6.19 |
| Bid | 6.16 |
| Offer | 6.19 |
| Previous close | 6.33 |
| Average volume | 176.20 |
|---|---|
| Shares outstanding | 260.32m |
| Free float | 259.37m |
| P/E (TTM) | 10.17 |
| Market cap | 1.90bn USD |
| EPS (TTM) | 0.7166 USD |
| Annual div (ADY) | 0.0679 EUR |
|---|---|
| Annual div yield (ADY) | 1.10% |
| Div ex-date | Feb 23 2026 |
| Div pay-date | Mar 12 2026 |
Data delayed at least 15 minutes, as of Feb 27 2026 07:00 GMT.
More ▼
Press releases
- New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
- Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
- Organon Completes Divestiture of JADA® System to Laborie
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
- Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
More ▼
